GlaxoSmithKline plc has insisted it remains open to selling its Consumer Healthcare business after a major investor called into question the firm’s plan to spin-off and list the unit.
Activist hedge fund Elliott Management recently wrote to the UK-based pharma giant’s board of directors arguing that the sale of...





